Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 5/20 | 1.00 |
| ▸ | ABL1 | P00519 | 11/20 | 0.81 |
| ▸ | KIT | P10721 | 10/20 | 0.76 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.73 |
| ▸ | FLT3 | P36888 | 2/20 | 0.73 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.73 |
| ▸ | MLNR | O43193 | 1/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.73 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14953298 | 0.97 | DDR1 (0.95) | DDR1ABL1KITDDR2FGFR1 | |
| SCHEMBL14953354 | 0.94 | DDR1 (0.90) | DDR1ABL1KITDDR2FGFR1 | |
| SCHEMBL14960097 | 0.94 | DDR1 (0.89) | DDR1ABL1KITDDR2FGFR1 | |
| SCHEMBL29514812 | 0.93 | DDR1 (0.87) | DDR1ABL1KITDDR2FGFR1 | |
| SCHEMBL14953211 | 0.93 | DDR1 (0.87) | DDR1ABL1KITDDR2FGFR1 | |
| SCHEMBL28522521 | 0.89 | DDR1 (0.80) | DDR1ABL1KITDDR2FGFR1 | |
| SCHEMBL31664731 | 0.89 | DDR1 (0.80) | DDR1ABL1KITDDR2FGFR1 | |
| SCHEMBL14953320 | 0.89 | DDR1 (0.80) | DDR1ABL1KITDDR2FGFR1 | |
| SCHEMBL14953329 | 0.89 | DDR1 (0.80) | DDR1ABL1KITDDR2FGFR1 | |
| SCHEMBL14953193 | 0.89 | DDR1 (0.80) | DDR1ABL1KITDDR2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2025-07-24 | — | — | US | claimed |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | claimed |
| EP-4460314-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| EP-3999056-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | claimed |
| US-20220142975-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | claimed |
| CN-112237579-A | Pharmaceutical composition and use thereof | 苏州亚盛药业有限公司 | 2021-01-19 | — | — | CN | claimed |
| EP-2594567-B1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | GUANGZHOU HEALTHQUEST PHARMA CO LTD (CN) | 2020-07-29 | — | — | EP | claimed |
| US-8846671-B2 | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-09-30 | — | — | US | claimed |
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzzhou Institute of Biomedicine and Health, Chineses Academy of Sciences (CN) | 2013-08-01 | — | — | US | claimed |
| EP-2594567-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2013-05-22 | — | — | EP | claimed |
| EP-3999056-B1 | PHARMACEUTICAL COMBINATION AND ITS USE IN THE PREVENTION AND TREATMENT OF CANCER | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2025-07-24 | — | — | US | disclosed |
| US-12351822-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-07-08 | — | — | US | disclosed |
| CN-101885722-B | Heterocycle alkyne and benzene compound, medicinal composition and application thereof | GUANGZHOU INST BIOMED & HEALTH | 2013-07-24 | — | — | CN | disclosed |
| EP-2594567-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594567-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012000304-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | 中国科学院广州生物医药与健康研究院 (CN) | 2012-01-05 | — | — | WO | disclosed |
| CN-101885722-A | Heterocycle alkyne and benzene compound, medicinal composition and application thereof | GUANGZHOU INST BIOMED & HEALTH | 2010-11-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | ABCB1, VHL, ABCC1 | DDR1 1290/4885ABL1 23/4885KIT 165/4885 |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | DCX, SLC10A2, CHAT | DDR1 3863/4885ABL1 3404/4885KIT 255/4885 |
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | SLC5A6, SLC10A1, SLC26A4 | DDR1 3071/4885ABL1 640/4885KIT 747/4885 |
| US-20220142975-A1 | Pharmaceutical Combination and Use Thereof | SLC5A6, SLC10A1, SLC26A4 | DDR1 3052/4885ABL1 653/4885KIT 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.